statins as modulators of bone formation他汀类药物作为骨形成的调节器.pdfVIP

Available online /content/4/3/151 Commentary Statins as modulators of bone formation Christopher J Edwards1 and Tim D Spector2 1Department of Rheumatology, Southampton General Hospital, Southampton, UK 2Twin Research and Genetic Epidemiology Unit, St Thomas’ Hospital, London, UK Correspondence: Dr Christopher J Edwards, Department of Rheumatology, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK. Tel: +44 (0)23 8079 8723; fax: +44 (0)23 8079 8529; e-mail: cedwards@soton.ac.uk Received: 4 October 2001 Arthritis Res 2002, 4:151-153 Revisions requested: 2 November 2001 This article may contain supplementary data which can only be found Revisions received: 20 November 2001 online at /content/4/3/151 Accepted: 22 November 2001 © 2002 BioMed Central Ltd Published: 21 January 2002 (Print ISSN 1465-9905; Online ISSN 1465-9913) Abstract The use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) to reduce serum cholesterol is well described. However, the recent finding that statins have direct effects on bone was unexpected. A number of epidemiological studies have recently been published that explore the effects of statins on bone mineral density and risk of fracture in humans. Statins may act by directly stimulating the expression of bone morphogenetic protein-2 and increasing osteoblast differentiation or, like nitrogen-containing bisphosphonates, may have effects on the mevalonate pathway that leads to